First, the retrospective design of the study prevented us from properly investigating various clinical and histopathological parameters, including BRAF, MSI, PD-1 (CD279), PD-L1 (CD274), and the immunological profiling of the tumor. The gene discussed is CD274; the disease is neoplasm.